Mycophenolate and hepatitis C: salve on a wound or gasoline on a fire?

Abstract

Liver TransplantationVolume 8, Issue 1 p. 47-49 EditorialFree Access Mycophenolate and hepatitis C: Salve on a wound or gasoline on a fire? Michael R. Charlton MD, Corresponding Author Michael R. Charlton MD [email protected] Division of Gastroenterology and Hepatology, Mayo Clinic, Rochester, MNMayo Clinic CH-10, Division of Gastroenterology and Hepatology, 200 First St SW, Rochester, MN 55902-3129. Telephone: 507-266-7054; FAX: 507-266-2810Search for more papers by this author Michael R. Charlton MD, Corresponding Author Michael R. Charlton MD [email protected] Division of Gastroenterology and Hepatology, Mayo Clinic, Rochester, MNMayo Clinic CH-10, Division of Gastroenterology and Hepatology, 200 First St SW, Rochester, MN 55902-3129. Telephone: 507-266-7054; FAX: 507-266-2810Search for more papers by this author First published: 30 December 2003 https://doi.org/10.1053/jlts.2002.29762Citations: 15AboutPDF ToolsRequest permissionExport citationAdd to favoritesTrack citation ShareShare Give accessShare full text accessShare full-text accessPlease review our Terms and Conditions of Use and check box below to share full-text version of article.I have read and accept the Wiley Online Library Terms and Conditions of UseShareable LinkUse the link below to share a full-text version of this article with your friends and colleagues. Learn more.Copy URL No abstract is available for this article. References 1 Choo QL, Kuo G, Weiner AJ, Overby LR, Bradley DW, Houghton M. Isolation of a cDNA clone derived from a blood-borne non-A, non-B viral hepatitis genome. Science 1989; 244: 359– 362.MEDLINE 2 Berenguer M, Ferrell L, Watson J, Prieto M, Kim M, Rayon M, et al. HCV-related fibrosis progression following liver transplantation: Increase in recent years. J Hepatol 2000; 32: 673– 684.MEDLINE 3 Berenguer M, Watson J, Crippin JS, Gish R, Bass NM, Baker C, et al. A model to predict HCV-related fibrosis progression following liver transplantation [abstract]. Hepatology 2001; 32: 217A. 4 Wiesner RH, Rabkin J, Klintmalm G, McDiarmid S, Langnas A, Punch J, et al. A randomized double-blind comparative study of mycophenolate mofetil and azathioprine in combination with cyclosporine and corticosteroids in primary liver transplant recipients. Liver Transpl 2001; 7: 442– 450.MEDLINE 5 Fasola CG, Netto G, Christensen LL, Molmenti EP, Gonwa T, Goldstein RM, Klintmalm GB. Natural history of recurrence of hepatitis C in liver transplant recipients under mycophenolate mofetil immunosuppression [abstract]. Liver Transpl 2001; 7: C31. 6 Rosen HR, Hinrichs DJ, Gretch DR, Koziel MJ, Chou S, Houghton M, et al. Association of multispecific CD4(+) response to hepatitis C and severity of recurrence after liver transplantation. Gastroenterology 1999; 117: 926– 932.MEDLINE 7 Neyts J, Andrei G, De Clercq E. The antiherpesvirus activity of H2G [(R)-9-[4-hydroxy-2-(hydroxymethyl)butyl]guanine] is markedly enhanced by the novel immunosuppressive agent mycophenolate mofetil. Antimicrob Agents Chemother 1998; 42: 3285– 3289.MEDLINE 8 Neyts J, De Clercq E. Mycophenolate mofetil strongly potentiates the anti-herpesvirus activity of acyclovir. Antiviral Res 1998; 40: 53– 56.MEDLINE 9 Neyts J, Andrei G, De Clercq E. The novel immunosuppressive agent mycophenolate mofetil markedly potentiates the antiherpesvirus activities of acyclovir, ganciclovir, and penciclovir in vitro and in vivo. Antimicrob Agents Chemother 1998; 42: 216– 222.MEDLINE 10 Neyts J, De Clercq E. The immunosuppressive agent mycophenolate mofetil markedly potentiates the activity of lobucavir [1R(1alpha,2beta,3alpha)]-9-[2,3-bis(hydroxymethyl)cyclobutyl]guanine against different herpes viruses. Transplantation 1999; 67: 760– 764.MEDLINE 11 McHutchison JG, Gordon SC, Schiff ER, Shiffman ML, Lee WM, Rustgi VK, et al. Interferon alfa-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C. Hepatitis Interventional Therapy Group. N Engl J Med 1998; 19: 1485– 1492. 12 Davis GL, Esteban-Mur R, Rustgi V, Hoefs J, Gordon SC, Trepo C, et al. Interferon alfa-2b alone or in combination with ribavirin for the treatment of relapse of chronic hepatitis C. International Hepatitis Interventional Therapy Group. N Engl J Med 1998; 19: 1493– 1499. 13 Gane EJ, Naoumov NV, Qian KP, Mondelli MU, Maertens G, Portmann BC, et al. A longitudinal analysis of hepatitis C virus replication following liver transplantation. Gastroenterology 1996; 110: 167– 177.MEDLINE 14 Charlton M, Seaberg E. Impact of immunosuppression and acute rejection on recurrence of hepatitis C: Results of the National Institute of Diabetes and Digestive and Kidney Diseases Liver Transplantation Database. Liver Transpl Surg 1999; 5(suppl): S107– S114.MEDLINE 15 Sheiner PA, Schwartz ME, Mor E, Schluger LK, Theise N, Kishikawa K, et al. Severe or multiple rejection episodes are associated with early recurrence of hepatitis C after orthotopic liver transplantation. Hepatology 1995; 21: 30– 34.MEDLINE Citing Literature Volume8, Issue1January 2002Pages 47-49 ReferencesRelatedInformation